Gerresheimer achieved solid results and continued to grow profitably in financial year 2024. Revenues reached EUR 2,035.9 million (2023: EUR 1,990.5 million), while adjusted EBITDA amounted to EUR 419.4 million (2023: EUR 404.5 million).
Organic sales grew by +2.9 percent and adjusted EBITDA by +4.1 percent. The adjusted EBITDA margin improved to 20.6 percent (2023: 20.3 percent). The Plastics & Devices Division benefited from the strong growth in medical devices, partially offsetting the destocking effects in the vial business in the Primary Packaging Glass Division. The first signs of a market recovery in the vial business were seen in the fourth quarter of 2024, but destocking effects at customers weighed on the results of the Primary Packaging Glass Division in the full year 2024.
Bormioli Pharma will contribute significantly to the Group’s revenues and Adjusted EBITDA from the financial year 2025 while the integration into the Gerresheimer Group is well underway. For the financial year 2025, the combined group of companies including Bormioli Pharma now expects organic revenue growth of 3-5 percent compared to combined pro forma figures of the previous year. The adjusted EBITDA margin is expected to improve further to around 22 percent. The Group anticipates profitable growth in the coming years through the consistent execution of its growth strategy.
“2024 was characterized by temporary market effects in one of our submarkets,” said Dietmar Siemssen, CEO of Gerresheimer AG. “Our long-term growth prospects remain positive. We are growing strongly in systems and solutions for large-molecule biologics for which we are systematically expanding our production capacities. With the acquisition of Bormioli Pharma, we have expanded our product portfolio and created the basis for new, integrated high value plastic solutions. All of this will help us to continue our profitable growth in the coming years.”
The Annual Report 2024 is available here.